Concepedia

Michael Torgov

MT

16

Publications

2.6K

Citations

13

H-Index

1998

Active since

Affiliations

Seagen (United States)(Current)

ImaginAb (United States)

Cornell University

Sepragen Corporation (United States)

City of Hope

Michael Torgov is an author at Seagen (United States) specializing in immunology, medicine, and immunotherapy.

Top concepts

Publications per year

1998–2024

16

Publications

16

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

, , +8

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders, Alexander J. Bankovich, Wade Anderson et al. · Science Translational Medicine · 2015 · 560 citations

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Michael Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry · 2005 · 359 citations · Full text

Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97

Leia M. Smith, Albina Nesterova, Stephen C. Alley et al. · Molecular Cancer Therapeutics · 2006 · 97 citations

Design, Synthesis, and in Vitro Evaluation of Dipeptide-Based Antibody Minor Groove Binder Conjugates

Scott C. Jeffrey, Michael Torgov, Jamie B. Andreyka et al. · Journal of Medicinal Chemistry · 2005 · 89 citations

Rows per page

1–5 of 16